Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-08-12 02:02 UTC

BIOMED PULSE

Wednesday, August 12, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the DRC has now surpassed 2,100 confirmed cases and 828 deaths as of July 15, making it the deadliest active outbreak on the planet right now. Mood: grimly watchful — multiple simultaneous outbreaks are stretching global response capacity while a handful of longevity-relevant drug and research signals offer cautious optimism.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (EBOLA), DRC AND UGANDA — CRITICAL

  • As of July 15, 2026, WHO confirmed 2,124 cases and 828 deaths from Bundibugyo virus disease (BVD) in the DRC, with sustained cross-border transmission into Uganda. [1]
  • The outbreak originated in Mongbwalu Health Zone, Ituri Province, DRC, first alerted to WHO on May 5, 2026; it has since expanded geographically over two months. [2]
  • CDC mobilized an international response beginning May 17, 2026, and enhanced Ebola airport screening has been deployed at Washington-Dulles International Airport and Atlanta Hartsfield-Jackson. [3][4][5]
  • Case fatality among confirmed cases has held near 39%, a hallmark of Bundibugyo virus, which is less lethal than Ebola Zaire but highly transmissible in healthcare settings. [6][1]

ANDES HANTAVIRUS, M/V HONDIUS CRUISE SHIP — MULTI-COUNTRY

  • WHO's fifth Disease Outbreak News update (July 2, 2026) confirmed ongoing Andes hantavirus (ANDV) cases linked to the M/V Hondius cruise ship, first reported May 2, 2026; ANDV is unusual for its documented person-to-person spread. [7]
  • CDC issued multiple transcript updates through June 24, 2026, noting the U.S. government considers public risk "extremely low" but continues active monitoring. [8]
  • Andes hantavirus causes hantavirus pulmonary syndrome, with case fatality rates historically between 25 and 35 percent.

CYCLOSPORA, TACO BELL ICEBERG LETTUCE — U.S. MULTISTATE

  • CDC identified shredded iceberg lettuce served at Taco Bell locations as the source of Cyclospora cayetanensis infections across five states, with 1,644 people reported sick as of July 17, 2026. [9]
  • The outbreak has since expanded to four additional states as of July 24, 2026; Cyclospora is a parasitic protozoan spread through contaminated produce. [10]
  • CDC issued a transcript update on Cyclosporiasis response on July 14, 2026.

SALMONELLA, JALAPEÑOS — U.S. MULTISTATE

  • CDC issued a food safety alert on August 5, 2026, warning of a multistate Salmonella outbreak linked to jalapeños.
  • This is the latest in a sustained wave of Salmonella outbreaks in 2026, which have also involved backyard poultry (34 sick across 13 states in April), pistachio cream, moringa leaf supplements, and frozen sprouted beans.

NIPAH VIRUS — INDIA

  • WHO confirmed one laboratory-confirmed Nipah virus (NiV) infection in Kozhikode district, Kerala State, India, on June 11, 2026, in an adult male who developed neurological symptoms on May 30.
  • Kozhikode has been the epicenter of previous NiV outbreaks in India; the virus carries a case fatality rate of 40 to 75 percent and has no approved specific treatment.

YELLOW FEVER — GLOBAL

  • WHO reported 79 human infections across six countries in the Americas from January 1 to May 26, 2026, following elevated transmission that began in 2025.
  • Yellow fever is vaccine-preventable; WHO urges travelers to endemic areas to confirm vaccination status.

MEASLES — BANGLADESH

  • WHO's April 23, 2026, DON confirmed 19,161 suspected measles cases and 2,897 laboratory-confirmed cases spreading across 58 of 64 districts in Bangladesh.
  • CDC separately reinforced national measles response in the U.S. through state collaboration as of March 9, 2026, following a Texas outbreak that caused two deaths in early 2025.

AVIAN INFLUENZA A(H9N2) — ITALY

  • WHO confirmed a human case of avian influenza A(H9N2) in Italy on March 21, 2026, in an adult male returning from Senegal; next-generation sequencing confirmed the subtype.
  • H9N2 rarely causes severe disease in humans but is considered a pandemic risk virus due to its wide poultry reservoir.

MPOX RECOMBINANT STRAIN — GLOBAL

  • WHO reported two cases of a recombinant MPXV strain combining clade Ib and clade IIb genomic elements in February 2026; recombination occurs when two strains co-infect the same individual.
  • The public health implications of this recombinant are under assessment; WHO notes recombination is a known natural process but warrants enhanced surveillance.

WEST NILE VIRUS — U.S.

  • CDC on July 1, 2026, warned of an early and record-breaking West Nile virus season and urged the public to use mosquito bite prevention measures over the July 4 holiday weekend.

LISTERIA, REQUESON/SOFT RICOTTA CHEESE — U.S.

  • CDC warned on June 5, 2026, of a Listeria monocytogenes outbreak linked to requesón and soft ricotta cheese.
  • Prior 2025-2026 Listeria outbreaks have been linked to deli meats, prepared meals, supplement shakes in long-term care facilities, and chicken fettuccine alfredo.

🧬 LONGEVITY & AGING

PUNICALAGIN AND BONE STEM CELL SENESCENCE

  • A Europe PMC study found that punicalagin, a polyphenol from pomegranates, alleviates senile osteoporosis by inhibiting senescence of bone mesenchymal stem cells via the NRF2/HO-1 antioxidant pathway in a preclinical model.
  • The NRF2/HO-1 axis is a key cellular defense against oxidative stress, which drives the aging-related decline in bone-forming stem cells; this points toward dietary polyphenols as potential senomorphic agents.

METFORMIN FOR PHYSICAL FUNCTION IN OLDER ADULTS WITH OBESITY (DEMFOS TRIAL)

  • A randomized controlled trial published in Lancet Healthy Longevity (DEMFOS trial) tested metformin added to lifestyle intervention for physical function in older adults with obesity; lead investigators include Nava, Viola, Aguilar, Bryant, Nambi, Armamento-Villareal, Qualls, and Villareal.
  • An accompanying editorial by Witham and McDonald in the same issue cautions that expectations for adjunctive metformin in obesity and frailty in older people may be inflated, calling for careful interpretation of effect sizes.
  • Metformin is already being studied as a longevity drug (TAME trial) partly for its AMPK-activating, anti-inflammatory properties.

LYSOSOMAL AMPK ACTIVATION FOR METABOLIC LIVER DISEASE

  • Research published in Bioactive Materials found that targeting ROAM1 with UDP-GlcNAc nanosheets selectively activates lysosomal AMPK, resolving metabolic dysfunction-associated steatotic liver disease (MASLD) in a preclinical model.
  • MASLD (formerly NAFLD) is increasingly recognized as an accelerant of biological aging; AMPK activation mimics some effects of caloric restriction.

COLLAGEN XVII AND EPIDERMAL STEM CELL PHOTOAGING

  • A study in Annals of Medicine found that recombinant human collagen XVII protects epidermal stem cells from blue-light-induced photoaging by downregulating the Notch signaling pathway.
  • Collagen XVII is a structural protein critical to skin stem cell anchoring; its depletion is a known mechanism of epidermal aging.

TELOMERE REPAIR AND CANCER CELL SENESCENCE

  • Research published in Nucleus examined repair and misrepair of telomeric DNA in dynamic interactions with PML nuclear bodies and lamin B1 in doxorubicin-treated cancer cells, by Salmina, Rumnieks, Pjanova, Vainshelbaum, and Erenpreisa.
  • Understanding telomere misrepair is relevant to both cancer and normal aging, as dysfunctional telomeres are a primary trigger of cellular senescence.

POSITIVE LIFE ORIENTATION AND BLOOD PRESSURE IN OLDER ADULTS

  • A study using two Finnish generational cohorts born 20 years apart found that positive life orientation is associated with lower blood pressure in older adults, published in Blood Press by Lääti, Teppo, Vire, Viitanen, and Langén.
  • The finding is notable because hypertension is one of the strongest modifiable risk factors for cardiovascular disease and accelerated brain aging.

MINIMALLY PROCESSED DIET AND CANINE EPIGENETIC AGING

  • A pilot study in Veterinary Record Open found that a minimally processed, human-grade diet altered epigenetic aging markers in dogs, suggesting diet quality influences the epigenetic clock across mammalian species.
  • Dogs are an established model for aging research because they share human environments and have accelerated epigenetic aging timelines useful for intervention studies.

UROLITHIN A AND GLUCOSE METABOLISM IN ADULTS 55 AND OLDER (CLINICAL TRIAL)

  • NCT06274749, a randomized triple-masked controlled trial, is evaluating urolithin A (UA) supplementation for glucose metabolism in healthy adults aged 55 and older.
  • UA is a gut microbiome-derived compound that activates mitophagy (clearance of damaged mitochondria) via the PINK1/Parkin pathway, a mechanism implicated in both metabolic and aging biology.

PET IMAGING OF PHOSPHODIESTERASE-4 IN ALZHEIMER DISEASE AND MCI (CLINICAL TRIAL)

  • NCT07169630 is imaging phosphodiesterase-4 (PDE4) in volunteers with Alzheimer disease (AD) or mild cognitive impairment (MCI) using PET scanning.
  • PDE4 regulates cyclic AMP signaling and neuroinflammation; its overactivation has been linked to cognitive decline and is a drug target under investigation.

DEPRESCRIBING TRIALS AND OLDER ADULTS

  • Two commentaries in Lancet Healthy Longevity argue that deprescribing trials — studies that test stopping or reducing medications in older adults — need a rationale-first framework before choosing trial design, to avoid methodological pitfalls.
  • Polypharmacy is a major driver of adverse outcomes in older adults; rigorous deprescribing evidence is considered a longevity-relevant priority.

💊 NEW CURES & APPROVALS

FOUNDAYO (ORFORGLIPRON CALCIUM) — ELI LILLY AND COMPANY

  • FDA records show a supplemental approval (SUPPL AP) action on NDA220934 for Foundayo, containing the active ingredient orforglipron calcium, sponsored by Eli Lilly and Co.
  • Orforglipron is an oral, non-peptide GLP-1 receptor agonist developed for type 2 diabetes and obesity — a mechanistic class that has also shown signals for metabolic and cardiovascular longevity benefits.

ORZEYFUL (OVEPOREXTON) — TAKEDA PHARMACEUTICALS USA

  • FDA records show an original approval (ORIG AP) on NDA220860 for Orzeyful, containing oveporexton, sponsored by Takeda Pharmaceuticals USA.
  • Oveporexton is an orexin 2 receptor agonist developed for the treatment of narcolepsy type 1, a condition defined by loss of orexin-producing hypothalamic neurons.

TRYVIO (APROCITENTAN) — IDORSIA

  • FDA records show a supplemental approval on NDA217686 for Tryvio, containing aprocitentan, sponsored by Idorsia.
  • Aprocitentan is a dual endothelin receptor antagonist (blocking both ETA and ETB receptors) indicated for resistant hypertension; uncontrolled hypertension is a key accelerant of vascular aging.

ADEMPAS (RIOCIGUAT) — BAYER HEALTHCARE

  • FDA records show a supplemental approval on NDA204819 for Adempas (riociguat), a soluble guanylate cyclase stimulator, sponsored by Bayer Healthcare.
  • Riociguat is approved for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension; the supplemental action likely expands an indication or updates labeling.

RANOLAZINE — UMEDICA

  • FDA records show an original approval (ORIG AP) on ANDA214551 for ranolazine, an antianginal agent that inhibits the late sodium current in cardiac cells, sponsored by Umedica.
  • This is a generic entry for an established cardiovascular indication.

LEVETIRACETAM — BAXTER HEALTHCARE CORP

  • FDA records show an original approval on ANDA208458 for levetiracetam (antiepileptic), sponsored by Baxter Healthcare Corp.

🧪 CLINICAL TRIALS

COGNITIVE REHABILITATION FOR POST-COVID-19 CONDITION — NCT05494424

  • A trial registered on ClinicalTrials.gov is testing Goal Management Training (GMT), a structured cognitive rehabilitation program targeting attention and executive functions, in patients with persistent post-COVID-19 cognitive sequelae.
  • GMT has prior empirical support in acquired brain injury populations; this trial extends it to long COVID, which affects millions globally.

BARICITINIB FOR JOB SYNDROME (HYPER-IgE) — NCT07262983

  • A trial is evaluating the safety and tolerability of baricitinib, a JAK1/JAK2 inhibitor (sponsor: NIH/NIAID), in patients with autosomal dominant hyper-IgE syndrome (Job syndrome) presenting with lupus-like disease or atopic dermatitis.
  • Baricitinib is already FDA-approved for rheumatoid arthritis and alopecia areata; this trial explores its use in a rare primary immunodeficiency with complex immune dysregulation.

ADVANCED CARE PLANNING FOR OLDER SURGICAL PATIENTS — NCT06090552

  • The I CAN DO Surgical ACP trial aims to encourage patients aged 65 and older referred for elective surgery to engage in advance care planning before their procedure.
  • Integrating ACP into pre-surgical workflows addresses a known gap: many older adults undergo major surgery without documented treatment preferences.

UROLITHIN A AND GLUCOSE METABOLISM IN ADULTS 55 PLUS — NCT06274749

  • A randomized triple-masked controlled trial (NCT06274749) is testing whether urolithin A supplementation improves pancreatic insulin secretion and blood glucose control in healthy adults aged 55 and older.
  • The trial targets age-related decline in beta-cell insulin release, a precursor to type 2 diabetes, via UA's mitophagy-activating mechanism.

EBV NANOPARTICLE VACCINE IN HEALTHY ADULTS — NCT06908096

  • A trial is testing an Epstein-Barr virus (EBV) gH/gL/gp42-ferritin nanoparticle vaccine, with or without a gp350-ferritin component, in healthy adults with or without prior EBV infection.
  • EBV infects over 90% of the global population and is causally linked to multiple sclerosis, several cancers, and chronic fatigue; an effective vaccine would have significant longevity implications.

ANTI-MESOTHELIN CAR T CELLS FOR SOLID TUMORS — NCT06885697

  • A trial is testing TNaive/SCM hYP218 (TNhYP218) CAR T cells targeting mesothelin in patients with mesothelin-expressing solid tumors including mesothelioma.
  • The use of naive/stem cell memory T cells (TNaive/SCM) as the starting population is a next-generation CAR T approach designed to improve persistence and reduce exhaustion compared to bulk T cell products.

DIGITAL DIETARY INTERVENTION WITH GLP-1 THERAPY — NCT07728669

  • NCT07728669 is testing whether the NutriSteppe digital dietary intervention added to routine GLP-1 receptor agonist therapy improves metabolic health in adults aged 21 to 65 with type 2 diabetes, obesity, or overweight.
  • The trial addresses a practical gap: GLP-1 agents produce greater benefit when combined with dietary change, but adherence to dietary modification is poorly supported in standard care.

📢 PUBLIC HEALTH

TIMOR-LESTE CERTIFIED MALARIA-FREE BY WHO

  • WHO certified Timor-Leste as malaria-free on July 23, 2025, recognizing a nationwide elimination effort launched shortly after the country's independence in 2002.
  • Timor-Leste joins a growing list of certified malaria-free nations; certification requires documented absence of indigenous transmission for at least three consecutive years.

U.S. COMPLETES WHO WITHDRAWAL

  • The United States formally completed its withdrawal from WHO on January 22, 2026, citing COVID-19 response failures and politicization of the organization.
  • WHO stated on January 24, 2026, that the withdrawal "makes both the United States and the world less safe" and that issues raised would be considered by the WHO Executive Board.

CDC TRAVELER-BASED GENOMIC SURVEILLANCE SURPASSES 1 MILLION PARTICIPANTS

  • CDC's Traveler-Based Genomic Surveillance program crossed one million voluntary air travel participants as of January 30, 2026, a biosurveillance milestone for early detection of emerging pathogens at borders.

CDC IMMUNIZATION SCHEDULE UPDATES COVID-19 AND HEPATITIS B GUIDANCE

  • As of October 2025, CDC updated its adult and child immunization schedules to apply individual-based decision-making for COVID-19 vaccination and standalone vaccination for chickenpox in toddlers.
  • In December 2025, CDC also adopted individual-based decision-making for hepatitis B immunization in infants born to women who test negative for hepatitis B virus, a shift from universal birth-dose policy.

DRUG-RESISTANT BACTERIA SHARP RISE

  • A CDC report released September 23, 2025, found a dramatic increase in a dangerous type of drug-resistant bacteria in the U.S.; antimicrobial resistance (AMR) is projected to kill 10 million people annually worldwide by 2050 if unaddressed.

INFANT BOTULISM LINKED TO POWDERED INFANT FORMULA

  • CDC on June 13, 2026, updated its outbreak investigation of infant botulism cases and urged parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula.

BIOMED PULSE is an informational digest grounded in official sources. Nothing here constitutes medical advice. Consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  4. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  5. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  6. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  7. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  8. Transcript - Update on CDC's Hantavirus Response - 6/24/26 — CDC Newsroom
  9. Shredded iceberg lettuce served at Taco Bell locations is sour… — CDC Newsroom
  10. Cyclospora outbreak linked to iceberg lettuce expanded to four… — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260812-02-v53 · 2026-08-12 02:02 UTC · pulse.uzylab.com

Read next